Rhythm Pharmaceuticals
RYTM
88.45
-2.32
-2.56%
Rhythm Pharmaceuticals
US · RYTM
#1874 by market cap
Listed 2017
88.45
-2.32
-2.56%
Live - 5344 symbols - heartbeat 436s ago
· 2026-10-08 07:27
Pre-market
88.00
-0.51%
After-hours
88.45
0.00%
Overnight
88.34
-0.12%
- Market cap
- 6.09B
- P/E (TTM)i
- -28.35
- P/Bi
- 59.12
- EPSi
- -3.11
- Div yieldi
- 0.00%
- 52W posi
- 29%
Reader sentiment
Are you bullish or bearish on RYTM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.3 percentage points.
Institutional ownership
- Held by institutions
- 113.31% -0.26pp
- Institutions
- 380 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund69.09%
Hedge Fund18.62%
VC/PE Fund16.22%
Public Company4.84%
Private Company2.38%
Sovereign Wealth Fund1.01%
Individual/Insider0.79%
Government Pension Fund0.56%
Family Office/Trust0.38%
Top holders as of 2026-06-30
RA Capital Management, L.P.
9.68% · 6.67M sh
BlackRock
8.94% · 6.16M sh
Baker Bros. Advisors LP
8.14% · 5.60M sh
Vanguard Capital Management, LLC
5.01% · 3.45M sh
PRIMECAP Management Company
4.60% · 3.17M sh
Vanguard Portfolio Management, LLC
4.56% · 3.14M sh
Perceptive Advisors LLC
3.76% · 2.59M sh
State Street Global Advisors
3.74% · 2.57M sh
T. Rowe Price Group, Inc.
3.73% · 2.57M sh
J.P. Morgan Asset Management, Inc.
3.72% · 2.56M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 28 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| David Meeker | Chairperson & CEO | 0.35% |
| Hunter Smith | Chief Financial Officer | 0.17% |
| Yann Mazabraud | Executive VP & Head of International | 0.08% |
| Pamela Cramer | Chief Human Resources Officer | 0.04% |
| Edward Mathers | Former Lead Independent Director | 0.03% |
| Joseph Shulman | Chief Technology Officer | 0.02% |
| Stuart Arbuckle | Former Independent Director | 0.02% |
| Jennifer Good | Former Independent Director | 0.02% |
| Lynn Tetrault | Former Independent Director | 0.02% |
| Christophe Jean | Former Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-13 | David Meeker | Chairperson & CEO | Derivative Exercise and Sale | -50,000 | $6.05–105.19 |
| 2026-08-30 | Hunter Smith | Chief Financial Officer | Automatic Disposition | -5,587 | $106.20 |
| 2026-08-30 | Hunter Smith | Chief Financial Officer | Derivative Exercise and Sale | -57,187 | $25.79–106.20 |
| 2026-08-16 | Manher Joshi | Chief Medical Officer | Other Derivative Acquisition | +25,000 | -- |
| 2026-08-16 | Manher Joshi | Chief Medical Officer | Other Derivative Acquisition | +50,000 | $115.44 |
| 2026-08-12 | Joseph Shulman | Chief Technology Officer | Automatic Disposition | -3,055 | $119.75 |
| 2026-08-12 | Joseph Shulman | Chief Technology Officer | Derivative Exercise and Sale | -2,024 | $6.80–119.75 |
| 2026-08-12 | Alastair Garfield | Former VP & Head of Research | Automatic Disposition | -7,763 | $116.11–119.17 |
| 2026-08-12 | Jennifer Lee | Executive VP & Head of North America | Automatic Disposition | -19,233 | $117.38 |
| 2026-08-12 | Jennifer Lee | Executive VP & Head of North America | Derivative Exercise and Sale | -56,601 | $6.80–117.38 |
| 2026-08-11 | Yann Mazabraud | Executive VP & Head of International | Automatic Disposition | -10,375 | $117.47 |
| 2026-08-11 | Yann Mazabraud | Executive VP & Head of International | Derivative Exercise and Sale | -46,625 | $6.80–117.47 |
| 2026-08-10 | Pamela Cramer | Chief Human Resources Officer | Intent to Sell (Form 144) | -11,406 | $115.48 |
| 2026-08-09 | Pamela Cramer | Chief Human Resources Officer | Intent to Sell (Form 144) | -3,520 | $115.63 |
| 2026-06-30 | Alastair Garfield | Former VP & Head of Research | Derivative Exercise and Sale | -2,150 | $110.41 |
| 2026-06-30 | Alastair Garfield | Former VP & Head of Research | Derivative Exercise and Retained | +2,295 | -- |
| 2026-06-23 | Jennifer Good | Former Independent Director | Other Derivative Acquisition | +2,324 | -- |
| 2026-06-23 | Jennifer Good | Former Independent Director | Other Derivative Acquisition | +3,691 | $107.55 |
| 2026-06-23 | David W. McGirr | Independent Director | Other Derivative Acquisition | +2,324 | -- |
| 2026-06-23 | David W. McGirr | Independent Director | Other Derivative Acquisition | +3,691 | $107.55 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:27:07 · For reference only, not investment advice and not tailored to your situation.